Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176458 | 0.95 | PAOX (0.37) | LMNATSHRLTA4HPAOXNAMPT | |
| SCHEMBL22336916 | 0.83 | TSHR (0.48) | LMNATSHR | |
| SCHEMBL22336918 | 0.79 | ALDH1A1 (0.39) | LMNATSHR | |
| SCHEMBL20176413 | 0.78 | TSHR (0.47) | LMNATSHRPAOXNAMPT | |
| SCHEMBL13123495 | 0.76 | LMNA (0.41) | LMNATSHRPAOXNAMPT | |
| SCHEMBL10044369 | 0.74 | TSHR (0.56) | LMNATSHRPAOX | |
| SCHEMBL6902756 | 0.74 | CYP2C19 (0.46) | LMNATSHR | |
| SCHEMBL18477609 | 0.74 | LMNA (0.43) | LMNATSHRPAOXNAMPT | |
| SCHEMBL21554109 | 0.74 | DEGS1 (0.41) | LMNATSHRPAOXNAMPT | |
| SCHEMBL12791495 | 0.73 | LMNA (0.46) | LMNAPAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | LMNA 3864/4885TSHR 1390/4885LTA4H 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.